S, L. G., F, M., D, C., K, B., G, C., O, C., . . . S, R. (2021). Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: A phase 1/2 trial. Blood, 137(7), 877. https://doi.org/10.1182/blood.2020008727
Chicago Style (17th ed.) CitationS, Le Gouill, et al. "Ibrutinib, Obinutuzumab, and Venetoclax in Relapsed and Untreated Patients with Mantle Cell Lymphoma: A Phase 1/2 Trial." Blood 137, no. 7 (2021): 877. https://doi.org/10.1182/blood.2020008727.
MLA (9th ed.) CitationS, Le Gouill, et al. "Ibrutinib, Obinutuzumab, and Venetoclax in Relapsed and Untreated Patients with Mantle Cell Lymphoma: A Phase 1/2 Trial." Blood, vol. 137, no. 7, 2021, p. 877, https://doi.org/10.1182/blood.2020008727.
Warning: These citations may not always be 100% accurate.
